Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA warns against compounded oral ketamine for psychiatric disorders

By Brian Buntz | October 30, 2023

Ketamine

[3D model of Ketamine from Wikimedia Commons]

In recent years, interest in the use of oral ketamine has surged for mood disorders, thanks to the marketing efforts of companies like Mindbloom, Better U, Nue Life and Joyous. FDA released a statement describing the risks involved in taking compounded oral ketamine, noting that the dissociative anesthetic is not FDA approved for any psychiatric disorder. 

Compounded oral ketamine risks

The agency specifically warned against the use of compounded ketamine without proper medical oversight, warning that sedation, dissociation, and vital sign changes “may put patients at risk for serious adverse events.” 

The FDA’s warning included several considerations related to the use of compounded ketamine for psychiatric disorders, including its potential for abuse and misuse. The agency also noted that ketamine use could lead to psychiatric events, given its association with dissociation and hallucinations. Ketamine is structurally similar to the fellow NMDA-receptor antagonist phencyclidine (PCP, angel dust), a drug frequently associated with inducing psychosis, but, 1962, the chemist Dr. Calvin L. Stevens synthesized ketamine as a safer alternative to that drug. Ketamine has less potent psychotomimetic (psychosis-mimicking) and dissociative effects compared to PCP, and offers more flexibility as an anesthetic. Ketamine also has one-tenth the potency of PCP. 

FDA also noted that ketamine can cause blood pressure increases, which could pose a risk for individuals with hypertension. Other potential adverse events from ketamine include respiratory depression.

Additionally, the FDA warned of the potential for lower urinary tract and bladder symptoms associated with ketamine use. It noted established safe or effective dosing for psychiatric indications is lacking, as ketamine has not been approved for these indications. 

The pandemic helped stoke interest in telehealth ketamine

Telehealth-based prescription of ketamine has grown in part as a result of the COVID-19 Public Health Emergency (PHE), which loosened requirements for in-person visits for controlled substances. Ketamine is a schedule III drug, in the same class as low-dose codeine and testosterone.  

Some professional organizations and journalists have called for increased scrutiny of at-home ketamine use as a result of safety and effectiveness concerns. After its debut in the 1970s, ketamine became a party drug in the following decades. Abuse of the drug receded in the 2000s
 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE